Phillip G. Febbo - Mar 4, 2025 Form 4 Insider Report for VERACYTE, INC. (VCYT)

Role
Chief Scientific & Med Officer
Signature
/s/ Jonathan Wygant, as attorney-in-fact
Stock symbol
VCYT
Transactions as of
Mar 4, 2025
Transactions value $
-$268,013
Form type
4
Date filed
3/6/2025, 04:42 PM
Previous filing
Mar 3, 2025
Next filing
Mar 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCYT Common Stock Sale -$147K -4.47K -4.93% $32.86 86.1K Mar 4, 2025 Direct F1, F2
transaction VCYT Common Stock Sale -$121K -3.57K -4.15% $33.95 82.5K Mar 4, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024.
F2 Represents weighted average sales price. Sale prices for the transactions range from $32.50 to $33.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F3 Represents weighted average sales price. Sale prices for the transactions range from $33.56 to $34.42. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.